Selective utilization of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer.

Molecular and Cellular Biology
R S CarterT Kadesch

Abstract

The microE3 E box within the immunoglobulin heavy-chain (IgH) enhancer binds several proteins of the basic helix-loop-helix-leucine zipper (bHLHzip) class, including TFE3, USF1, and Max. Both TFE3 and USF have been described as transcriptional activators, and so we investigated their possible roles in activating the IgH enhancer in vivo. Although TFE3 activated various enhancer-based reporters, both USF1 and Max effectively inhibited transcription. Inhibition by USF correlated with the lack of a strong activation domain and was the result of the protein neutralizing the microE3 site. The effects of dominant-negative derivatives of TFE3 and USF1 confirmed that TFE3, or a TFE3-like protein, is the primary cellular bHLHzip protein that activates the IgH enhancer. In addition to providing a physiological role for TFE3, our results call into question the traditional view of USF1 as an obligate transcriptional activator.

References

Oct 1, 1992·Nature·L KretznerR N Eisenman
May 1, 1992·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L A Eckhardt
Apr 1, 1992·Current Opinion in Genetics & Development·E M BlackwoodR N Eisenman
Jan 1, 1991·Genes & Development·D RuezinskyT Kadesch
Feb 1, 1991·Molecular and Cellular Biology·C MurreD Baltimore
Jun 1, 1991·Genes & Development·H Beckmann, T Kadesch
Aug 1, 1990·Molecular and Cellular Biology·C S Carr, P A Sharp
Dec 1, 1989·Trends in Genetics : TIG·K L Calame
Feb 1, 1987·Molecular and Cellular Biology·J R de WetS Subramani
Apr 1, 1973·Virology·F L Graham, A J van der Eb
Aug 1, 1995·Molecular and Cellular Biology·C P Shen, T Kadesch
Dec 1, 1994·Molecular and Cellular Biology·S E ArtandiK Calame
Jan 1, 1993·Molecular and Cellular Biology·C AminN Hay
Jan 19, 1996·The Journal of Biological Chemistry·B ViolletA Martinez

❮ Previous
Next ❯

Citations

May 23, 1998·Annual Review of Immunology·A Henderson, K Calame
Mar 29, 2000·Proceedings of the National Academy of Sciences of the United States of America·J WangP D Aplan
Apr 20, 2006·Journal of Cellular Biochemistry·Li QiPaul J Higgins
Sep 17, 2004·Journal of Cellular Physiology·Rosalie R AllenPaul J Higgins
Jun 6, 2014·Journal of Virology·Aimee N ReedLing Jin
Sep 16, 2005·Pigment Cell Research·Sébastien Corre, Marie-Dominique Galibert
Nov 12, 2005·Molecular Endocrinology·David A RossTom Kadesch
Apr 7, 1998·Molecular and Cellular Biology·P OrdentlichT Kadesch
Aug 18, 2001·Molecular and Cellular Biology·F ZhaoJ K Choi
Sep 16, 2004·Molecular and Cellular Biology·Siyuan SongJohn Kim Choi
Oct 17, 1998·Molecular and Cellular Biology·W DangR Sen
May 28, 1998·The Journal of Biological Chemistry·J L BessereauJ P Changeux
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·C A MundtM Brüggemann
Jun 11, 1999·The American Journal of Physiology·A D Johnson, G K Owens
Jun 1, 1997·Molecular and Cellular Biology·K MerrellK Calame
Feb 1, 2002·Biochemical and Biophysical Research Communications·Jun Lu, Steven R Sloan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.